Study: This Assessment Better Captures Daytime Benefits of Insomnia Treatments
Retrospective questionnaires may miss the true impact of treatments on symptoms such as daytime functioning.
Tag: Merck
All
Latest
All
LatestBELSOMRA Meets Primary Efficacy Endpoint in Trial for Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease
At the American Academy of Neurology annual meeting, researchers presented the results of a phase 3 trial evaluating the efficacy and safety of Merck’s BELSOMRA (suvorexant) C-IV for the treatment of insomnia in people...
